Table 2.
Comparison of DLL3 expression levels and clinicopathological characteristics in neuroendocrine carcinomas by tumor type
| Characteristics | Bladder | Head&Neck | Lung* | Uterine cervix** | Skin*** | Thyroid**** | Prostate | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCC (n = 19) | NEC (n = 19) | NEC (n = 45) | NEC (n = 21) | MCC (n = 33) | MC (n = 74) | SCC (n = 16) | ||||||||||||||||||||||||
| N | % | Median Total H-score | P value | N | % | Median Total H-score | P value | N | % | Median Total H-score | P value | N | % | Median Total H-score | P value | N | % | Median Total H-score | P value | N | % | Median Total H-score | P value | N | % | Median Total H-score | P value | |||
| Sex | F | 1 | 5.3 | NA | NA | 7 | 36.8 | 40 | 0.36 | 19 | 42.2 | 50 | 0.019 | 21 | 100.0 | 125 | NA | 8 | 24.2 | 150 | 0.94 | 34 | 45.9 | 0 | 0.086 | 0 | 0.0 | NA | NA | |
| M | 17 | 89.5 | 80 | 11 | 57.9 | 7 | 26 | 57.8 | 140 | 0 | 0.0 | NA | 21 | 63.6 | 145 | 37 | 50.0 | 0 | 16 | 100.0 | 115 | |||||||||
| uk | 1 | 5.3 | NA | 1 | 5.3 | NA | 0 | 0.0 | NA | 0 | 0.0 | NA | 4 | 12.1 | 50 | 3 | 4.1 | 0 | 0 | 0.0 | NA | |||||||||
| Stage | I/II | 8 | 42.1 | 38.5 | 0.52 | 2 | 10.5 | 62 | 0.67 | 26 | 57.8 | 87.5 | 0.24 | 11 | 52.4 | 115 | 0.39 | 10 | 30.3 | 125 | 0.42 | 24 | 32.4 | 0 | 0.66 | 2 | 12.5 | 132 | 0.75 | |
| III/IV | 8 | 42.1 | 120 | 1 | 5.3 | NA | 14 | 31.1 | 140 | 7 | 33.3 | 125 | 19 | 57.6 | 145 | 44 | 59.5 | 0 | 10 | 62.5 | 118 | |||||||||
| uk | 3 | 15.8 | 70 | 16 | 84.2 | 8 | 5 | 11.1 | 0 | 3 | 14.3 | 135 | 4 | 12.1 | 50 | 6 | 8.1 | 0 | 4 | 25.0 | 27.5 | |||||||||
| Previous Treatment | No | 9 | 47.4 | 70 | 0.7 | 18 | 94.7 | 12.5 | NA | 33 | 73.3 | 95 | 0.71 | 14 | 66.7 | 120 | 0.34 | 18 | 54.5 | 148 | 0.79 | 70 | 94.6 | 0 | NA | 0 | 0.0 | NA | NA | |
| Yes | 8 | 42.1 | 87.5 | 0 | 0.0 | NA | 9 | 20.0 | 105 | 2 | 9.5 | 7 | 11 | 33.3 | 145 | 0 | 0.0 | NA | 2 | 12.5 | 125 | |||||||||
| uk | 2 | 10.5 | 100 | 1 | 5.3 | NA | 3 | 6.7 | 40 | 5 | 23.8 | 125 | 4 | 12.1 | 50 | 4 | 5.4 | 0 | 14 | 87.5 | 115 | |||||||||
| Recurrence at 5 years | No | 8 | 42.1 | 97.5 | 0.6 | 7 | 36.8 | 0 | 0.067 | 27 | 60.0 | 80 | 0.47 | 6 | 28.6 | 70.5 | 0.68 | 16 | 48.5 | 150 | 0.87 | 54 | 73.0 | 0 | 0.24 | 3 | 18.8 | 145 | 0.036 | |
| Yes | 2 | 10.5 | 75 | 7 | 36.8 | 55 | 12 | 26.7 | 112 | 9 | 42.9 | 130 | 12 | 36.4 | 145 | 9 | 12.2 | 0 | 5 | 31.3 | 55 | |||||||||
| uk | 9 | 47.4 | 70 | 5 | 26.3 | 16 | 6 | 13.3 | 140 | 6 | 28.6 | 118 | 5 | 15.2 | 86 | 11 | 14.9 | 0 | 8 | 50.0 | 118 | |||||||||
| Survival at 5 years | D | 15 | 78.9 | 70 | 0.99 | 12 | 63.2 | 47.5 | 0.21 | 28 | 62.2 | 80 | 0.87 | 13 | 61.9 | 130 | 0.86 | 13 | 39.4 | 140 | 0.24 | 17 | 23.0 | 0 | 0.66 | 10 | 62.5 | 115 | 0.33 | |
| A | 2 | 10.5 | 85 | 6 | 31.6 | 2 | 17 | 37.8 | 105 | 6 | 28.6 | 130 | 16 | 48.5 | 155 | 51 | 68.9 | 0 | 6 | 37.5 | 125 | |||||||||
| uk | 2 | 10.5 | 100 | 1 | 5.3 | NA | 0 | 0.0 | NA | 2 | 9.5 | 67.5 | 4 | 12.1 | 50 | 6 | 8.1 | 0 | 0 | 0.0 | NA | |||||||||
| DLL3 IHC site | M/R | 0 | 0.0 | NA | NA | 4 | 21.1 | 8 | 0.9 | 3 | 6.7 | 40 | 0.26 | 0 | 0.0 | NA | NA | 5 | 15.2 | 82 | 0.16 | 0 | 0.0 | NA | NA | 10 | 62.5 | 115 | 0.85 | |
| P | 19 | 100.0 | 70 | 12 | 63.2 | 22 | 42 | 93.3 | 100 | 21 | 100.0 | 125 | 24 | 72.7 | 145 | 72 | 97.3 | 0 | 5 | 31.3 | 135 | |||||||||
| uk | 0 | 0.0 | NA | 3 | 15.8 | 16 | 0 | 0.0 | NA | 0 | 0.0 | NA | 4 | 12.1 | 79 | 2 | 2.7 | 0 | 1 | 6.3 | NA | |||||||||
| Smoking status | C | 0 | 0.0 | NA | 0.88 | 1 | 5.3 | NA | 0.21 | 32 | 71.1 | 50 | 0.07 | 1 | 4.8 | NA | 0.56 | 0 | 0.0 | NA | 0.43 | 3 | 4.1 | 0 | 0.76 | 2 | 12.5 | 82.5 | 0.73 | |
| FR | 11 | 57.9 | 70 | 6 | 31.6 | 7 | 13 | 28.9 | 95 | 2 | 9.5 | 142.7 | 11 | 33.3 | 135 | 20 | 27.0 | 0 | 5 | 31.3 | 140 | |||||||||
| N | 6 | 31.6 | 130 | 7 | 36.8 | 16 | 0 | 0.0 | NA | 18 | 85.7 | 130 | 22 | 66.7 | 147.5 | 51 | 68.9 | 0 | 8 | 50.0 | 110 | |||||||||
| uk | 2 | 10.5 | 100 | 5 | 26.3 | 65 | 0 | 0.0 | NA | 0 | 0.0 | NA | 0 | 0.0 | NA | 0 | 0.0 | NA | 0 | 0.0 | NA | |||||||||
SCC small cell carcinoma, NEC neuroendocrine carcinoma, *SCLC Small lung cell carcinoma, LCNEC large cell neuroendocrine carcinoma; and combined histology, **SCNEC small cell neuroendocrine carcinoma, LCNEC large cell neuroendocrine carcinoma; and combined histology, ***MCC Merkel cell carcinoma, ****MC medullary carcinoma, F female, M male, uk unknown, D death, A alive, M/R metastasis or recurrence, P primary, C current, FR former, N never.